Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies

Publisher： Karger

E-ISSN： 1423-0194|97|1|86-98

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.97, Iss.1, 2012-05, pp. : 86-98

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Orthotopic Model of Pancreatic Somatostatin Receptor (SSTR)-Positive Tumors Allows Bimodal Imaging Studies Using 3T MRI and Animal PET-Based Molecular Imaging of SSTR Expression

By  

Neuroendocrinology, Vol. 87, Iss. 4, 2007-11 ,pp. : 233-242

Karger

Access to resources Recommend Favorite

Future Aspects of Somatostatin- Receptor-Mediated Therapy

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 57-61

Karger

Access to resources Recommend Favorite

Growth Hormone-Secreting Tumors: Genetic Aspects and Data from Animal Models

By  

Neuroendocrinology, Vol. 83, Iss. 3-4, 2006-10 ,pp. : 166-178

Karger

Access to resources Recommend Favorite

Targeted Radionuclide Therapy for Neuroendocrine Tumours: Principles and Application

By  

Neuroendocrinology, Vol. 91, Iss. 1, 2009-07 ,pp. : 1-15

Karger

Access to resources Recommend Favorite

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

By  

Neuroendocrinology, Vol. 93, Iss. 3, 2011-02 ,pp. : 189-196

Karger

Access to resources Recommend Favorite